Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
1hOpinion
We must stay vigilant on false patent extensions and the non-clinical use of weight-loss drugs
The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...
Zacks Investment Research on MSN
CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback